Successful Management of BRAF V600E–Mutated Metastatic Colorectal Cancer With Liver Dysfunction Using Encorafenib-Based Therapy
Journal of the National Comprehensive Cancer Network · 2026-07 · 24 (7)
DOI: 10.6004/jnccn.2026.7003 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026-07. Verfasst von Celine Hoyek und 5 weiteren Autor:innen. Beteiligte Einrichtung: 1Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Carbamates, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
The recent approval of encorafenib, cetuximab, and FOLFOX based on the phase III BREAKWATER trial has introduced a new standard of care for the first-line treatment of BRAF V600E–mutated metastatic colorectal cancer (mCRC). However, its safety and efficacy in patients with significant liver dysfunction remains unclear and, as such, patients are often excluded from pivotal clinical trials. This report presents a case of BRAF V600E–mutated mCRC presenting with extensive hepatic involvement and liver dysfunction. Despite the absence of guidelines, the patient was initiated on full-dose encorafenib, cetuximab, and FOLFOX. He experienced a rapid clinical and biochemical response, with near-normalization of liver enzymes after cycle 1, and complete functional recovery by cycle 3. Treatment was well tolerated, with no significant adverse events throughout 9 cycles. He subsequently transitioned to maintenance 5-FU, cetuximab, and encorafenib. Posttreatment blood-based next-generation sequencing revealed no residual actionable mutations. The patient then successfully underwent complete surgical resection of his primary tumor and metastatic disease with negative margins. This case highlights the importance of considering encorafenib-based therapy in select patients with BRAF V600E–mutated mCRC in the setting of compromised liver function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ.
- 2Department of Biomedical Sciences, Humanitas University, Milan, Italy.
- 3Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
- 4Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL.
Zitieren
APA
Hoyek, C., Pirozzi, A., Rone, K., Wu, C., Jones, J., & Bekaii-Saab, T. (2026). Successful Management of BRAF V600E–Mutated Metastatic Colorectal Cancer With Liver Dysfunction Using Encorafenib-Based Therapy. Journal of the National Comprehensive Cancer Network, 24(7). https://doi.org/10.6004/jnccn.2026.7003
Vancouver
Hoyek C, Pirozzi A, Rone K, Wu C, Jones J, Bekaii-Saab T. Successful Management of BRAF V600E–Mutated Metastatic Colorectal Cancer With Liver Dysfunction Using Encorafenib-Based Therapy. Journal of the National Comprehensive Cancer Network. 2026;24(7). doi:10.6004/jnccn.2026.7003
BibTeX
@article{Hoyek2026,
author = {Hoyek, Celine and Pirozzi, Angelo and Rone, Kelley and Wu, Christina and Jones, Jeremy and Bekaii-Saab, Tanios},
title = {Successful Management of BRAF V600E–Mutated Metastatic Colorectal Cancer With Liver Dysfunction Using Encorafenib-Based Therapy},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2026},
volume = {24},
number = {7},
doi = {10.6004/jnccn.2026.7003}
}
EUVIMED